ADCETRIS® (brentuximab vedotin) Prescribing Information

ADCETRIS® as a treatment option for your suitable adult patients with CD30+ Hodgkin lymphoma1

ADCETRIS is indicated for use in Hodgkin lymphoma (HL) for adult patients with1:

  • Previously untreated CD30+ Stage 3 or 4 HL in combination with doxorubicin, vinblastine and dacarbazine (AVD)
  • Previously untreated CD30+ Stage 2B with risk factors, Stage 3 or Stage 4 HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (ECADD)
  • CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT)
  • Relapsed or refractory CD30+ HL:
    1. Following ASCT or
    2. Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

Funding status

ADCETRIS is both NICE recommended and SMC accepted for use in combination with AVD as an option for untreated stage 3 or 4 CD30+ Hodgkin lymphoma in adults.2,3

ADCETRIS is also NICE recommended and SMC accepted as an option for treating adults with CD30+ Hodgkin lymphoma with relapsed or refractory disease if they have already had ASCT or have had at least two previous therapies when ASCT or multi-agent chemotherapy were not suitable.4,5

For more information on NHS funding of ADCETRIS, please refer to the Blueteq criteria where applicable.6

ADCETRIS key safety information

Please consult the Summary of Product Characteristics before prescribing ADCETRIS and for full information about dosing, administration, contraindications, special warnings and tolerability profile.

When used as monotherapy (across HL, sALCL and CTCL studies), the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, neutropenia, upper respiratory tract infection, arthralgia, rash, cough, vomiting, pruritus, peripheral motor neuropathy, infusion-related reactions, constipation, dyspnoea, myalgia, weight decreased, and abdominal pain.1

When used in combination therapy with AVD (in previously untreated stage 3 or 4 HL) and CHP (in previously untreated sALCL), the most frequent adverse reactions (≥10%) were infections, neutropenia, peripheral sensory neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia, alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia, myalgia, back pain, peripheral motor neuropathy, upper respiratory tract infection, and dizziness.1

A healthcare professional wearing a white coat and stethoscope is seated at a desk, holding a clipboard and pen while speaking with another person across the table in a bright clinical setting.

Further information

Click here for key data supporting the safety and efficacy of ADCETRIS in combination with AVD for adult patients with previously untreated CD30+ Stage 3 or 4 HL.

Click here for data summary

ASCT, autologous stem cell transplant; AVD, doxorubicin, vinblastine, dacarbazine; ECADD, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; HL, Hodgkin lymphoma; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium. 

1. ADCETRIS Summary of Product Characteristics; 2. NICE TA1059. Available at: www.nice.org.uk/guidance/ta1059/chapter/1-Recommendation; 3. SMC 2762. Available at: scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-full-smc2762; 4. NICE TA524. Available at: www.nice.org.uk/guidance/TA524/chapter/1-recommendations; 5. SMC 845/12. Available at: scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-fullsubmission-84512; 6. Cancer Drugs Fund List. Available at: https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/.

To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.